<DOC>
	<DOC>NCT01757535</DOC>
	<brief_summary>This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) following induction with or without consolidation chemotherapy. Subjects who have previously achieved CR/CRi with a hypomethylating agent will be excluded from the study.</brief_summary>
	<brief_title>Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission</brief_title>
	<detailed_description>This is an international, multicenter, placebo-controlled, phase3 study with a double-blind, randomized, parallel-group design with de novo AML (Acute Myeloid Leukemia) or AML secondary to prior diagnosis of Myelodysplasic Syndromes (MDS) or chronic myelomonocytic leukemia (CMML)</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1. Male or female subjects â‰¥ 55 years of age 2. Newly diagnosed, histologically confirmed de novo AML or AML secondary to prior myelodysplastic disease or CMML (Chronic myelomonocytic leukemia) 3. First Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) with induction therapy + consolidation therapy within 4 months (+/ 7 days of achieving CR or CRi) 4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2, 3 1. AML with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) or molecular evidence of such translocations 2. Prior bone marrow or stem cell transplantation 3. Have achieved CR/CRi following therapy with hypomethylating agents 4. Diagnosis of malignant disease within the previous 12 months 5. Proven Central Nervous System (CNS) leukemia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Maintenance therapy</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>oral Azacitidine</keyword>
	<keyword>best supportive care</keyword>
	<keyword>complete remission</keyword>
</DOC>